FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914381505> ?p ?o ?g. }

• W2914381505 endingPage "1335" @default.
• W2914381505 startingPage "1326" @default.
• W2914381505 abstract "Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour infusion. The coprimary outcomes were the percent change in anti-factor Xa activity after andexanet treatment and the percentage of patients with excellent or good hemostatic efficacy at 12 hours after the end of the infusion, with hemostatic efficacy adjudicated on the basis of prespecified criteria. Efficacy was assessed in the subgroup of patients with confirmed major bleeding and baseline anti-factor Xa activity of at least 75 ng per milliliter (or ≥0.25 IU per milliliter for those receiving enoxaparin).Patients had a mean age of 77 years, and most had substantial cardiovascular disease. Bleeding was predominantly intracranial (in 227 patients [64%]) or gastrointestinal (in 90 patients [26%]). In patients who had received apixaban, the median anti-factor Xa activity decreased from 149.7 ng per milliliter at baseline to 11.1 ng per milliliter after the andexanet bolus (92% reduction; 95% confidence interval [CI], 91 to 93); in patients who had received rivaroxaban, the median value decreased from 211.8 ng per milliliter to 14.2 ng per milliliter (92% reduction; 95% CI, 88 to 94). Excellent or good hemostasis occurred in 204 of 249 patients (82%) who could be evaluated. Within 30 days, death occurred in 49 patients (14%) and a thrombotic event in 34 (10%). Reduction in anti-factor Xa activity was not predictive of hemostatic efficacy overall but was modestly predictive in patients with intracranial hemorrhage.In patients with acute major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly reduced anti-factor Xa activity, and 82% of patients had excellent or good hemostatic efficacy at 12 hours, as adjudicated according to prespecified criteria. (Funded by Portola Pharmaceuticals; ANNEXA-4 ClinicalTrials.gov number, NCT02329327.)." @default.
• W2914381505 created "2019-02-21" @default.
• W2914381505 creator A5000735539 @default.
• W2914381505 creator A5003814460 @default.
• W2914381505 creator A5004003194 @default.
• W2914381505 creator A5011390057 @default.
• W2914381505 creator A5011503121 @default.
• W2914381505 creator A5015513362 @default.
• W2914381505 creator A5020373936 @default.
• W2914381505 creator A5021971603 @default.
• W2914381505 creator A5025216050 @default.
• W2914381505 creator A5025721214 @default.
• W2914381505 creator A5038564609 @default.
• W2914381505 creator A5045294368 @default.
• W2914381505 creator A5046643965 @default.
• W2914381505 creator A5046765231 @default.
• W2914381505 creator A5051336132 @default.
• W2914381505 creator A5051569650 @default.
• W2914381505 creator A5053120888 @default.
• W2914381505 creator A5054604221 @default.
• W2914381505 creator A5055162008 @default.
• W2914381505 creator A5057802451 @default.
• W2914381505 creator A5060066252 @default.
• W2914381505 creator A5061508608 @default.
• W2914381505 creator A5063761734 @default.
• W2914381505 creator A5075659307 @default.
• W2914381505 creator A5079046512 @default.
• W2914381505 creator A5079941141 @default.
• W2914381505 creator A5081541193 @default.
• W2914381505 creator A5081749777 @default.
• W2914381505 creator A5086053015 @default.
• W2914381505 creator A5087630518 @default.
• W2914381505 date "2019-04-04" @default.
• W2914381505 modified "2023-10-14" @default.
• W2914381505 title "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors" @default.
• W2914381505 cites W1980009210 @default.
• W2914381505 cites W2034607173 @default.
• W2914381505 cites W2097854437 @default.
• W2914381505 cites W2115787552 @default.
• W2914381505 cites W2158698691 @default.
• W2914381505 cites W2162508946 @default.
• W2914381505 cites W2163311091 @default.
• W2914381505 cites W2166402206 @default.
• W2914381505 cites W2174386486 @default.
• W2914381505 cites W2236351932 @default.
• W2914381505 cites W2514338974 @default.
• W2914381505 cites W2749380187 @default.
• W2914381505 cites W2750504927 @default.
• W2914381505 cites W2781949590 @default.
• W2914381505 cites W2791026080 @default.
• W2914381505 cites W4254642512 @default.
• W2914381505 doi "https://doi.org/10.1056/nejmoa1814051" @default.
• W2914381505 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6699827" @default.
• W2914381505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30730782" @default.
• W2914381505 hasPublicationYear "2019" @default.
• W2914381505 type Work @default.
• W2914381505 sameAs 2914381505 @default.
• W2914381505 citedByCount "610" @default.
• W2914381505 countsByYear W29143815052019 @default.
• W2914381505 countsByYear W29143815052020 @default.
• W2914381505 countsByYear W29143815052021 @default.
• W2914381505 countsByYear W29143815052022 @default.
• W2914381505 countsByYear W29143815052023 @default.
• W2914381505 crossrefType "journal-article" @default.
• W2914381505 hasAuthorship W2914381505A5000735539 @default.
• W2914381505 hasAuthorship W2914381505A5003814460 @default.
• W2914381505 hasAuthorship W2914381505A5004003194 @default.
• W2914381505 hasAuthorship W2914381505A5011390057 @default.
• W2914381505 hasAuthorship W2914381505A5011503121 @default.
• W2914381505 hasAuthorship W2914381505A5015513362 @default.
• W2914381505 hasAuthorship W2914381505A5020373936 @default.
• W2914381505 hasAuthorship W2914381505A5021971603 @default.
• W2914381505 hasAuthorship W2914381505A5025216050 @default.
• W2914381505 hasAuthorship W2914381505A5025721214 @default.
• W2914381505 hasAuthorship W2914381505A5038564609 @default.
• W2914381505 hasAuthorship W2914381505A5045294368 @default.
• W2914381505 hasAuthorship W2914381505A5046643965 @default.
• W2914381505 hasAuthorship W2914381505A5046765231 @default.
• W2914381505 hasAuthorship W2914381505A5051336132 @default.
• W2914381505 hasAuthorship W2914381505A5051569650 @default.
• W2914381505 hasAuthorship W2914381505A5053120888 @default.
• W2914381505 hasAuthorship W2914381505A5054604221 @default.
• W2914381505 hasAuthorship W2914381505A5055162008 @default.
• W2914381505 hasAuthorship W2914381505A5057802451 @default.
• W2914381505 hasAuthorship W2914381505A5060066252 @default.
• W2914381505 hasAuthorship W2914381505A5061508608 @default.
• W2914381505 hasAuthorship W2914381505A5063761734 @default.
• W2914381505 hasAuthorship W2914381505A5075659307 @default.
• W2914381505 hasAuthorship W2914381505A5079046512 @default.
• W2914381505 hasAuthorship W2914381505A5079941141 @default.
• W2914381505 hasAuthorship W2914381505A5081541193 @default.
• W2914381505 hasAuthorship W2914381505A5081749777 @default.
• W2914381505 hasAuthorship W2914381505A5086053015 @default.
• W2914381505 hasAuthorship W2914381505A5087630518 @default.
• W2914381505 hasBestOaLocation W29143815051 @default.
• W2914381505 hasConcept C126322002 @default.
• W2914381505 hasConcept C141071460 @default.
• W2914381505 hasConcept C176674119 @default.

• next